AstraZeneca PLC (AZN)
| Market Cap | 301.34B +32.2% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 29.01 |
| Forward PE | 18.28 |
| Dividend | $3.20 (1.64%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 650,313 |
| Open | 189.52 |
| Previous Close | 183.86 |
| Day's Range | 189.17 - 196.41 |
| 52-Week Range | 134.90 - 212.71 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 224.29 (+14.93%) |
| Earnings Date | Jul 27, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $224.29, which is an increase of 14.93% from the latest price.
News
AstraZeneca signs CSPC China deal for experimental kidney disease drugs
AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese ...
Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Therapy
Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Therapy
Abbisko Therapeutics And AstraZeneca Enter Strategic Collaboration For Lumipodlin
(RTTNews) - Abbisko Therapeutics Co., Ltd (2256.HK), announced that it has entered into a strategic collaboration with AstraZeneca (AZN) to jointly advance the clinical development of a novel IO-TKI c...
AstraZeneca, Abbisko Therapeutics enter strategic collaboration
Abbisko Therapeutics announced that it has entered into a strategic collaboration agreement with AstraZeneca (AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for...
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreeme...
AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Tells Investors
AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Tells Investors
AstraZeneca (AZN) Faces Competition from Anthropic's New AI in Pharma Research
AstraZeneca (AZN) Faces Competition from Anthropic's New AI in Pharma Research
AstraZeneca (AZN) Secures EU Approval for Enhertu in Cancer Treatment
AstraZeneca (AZN) Secures EU Approval for Enhertu in Cancer Treatment
AstraZeneca announces Enhertu approval in EU for HER2 positive solid tumors
Enhertu has been approved in the European Union, or EU, as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors who have received…
AstraZeneca announces results from the MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa demonstrated a statistically significant and clinically meaningful improvement in bone health in children with hypophosp...
AstraZeneca (AZN) Receives EU Approval Recommendation for Breast Cancer Treatment
AstraZeneca (AZN) Receives EU Approval Recommendation for Breast Cancer Treatment
AstraZeneca reports Datroway recommended for approval in EU by CHMP
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Datroway has been recommended for approval in the European Union as monotherapy for the first-line treatment of adult patients with unresectable or metas...
Daiichi Sankyo: Datroway Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary...
For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.
AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.
Top FTSE Shares for Beginners to Buy in 2026: AZN, REL and RR.
Three FTSE shares for beginners stand out heading into 2026: AstraZeneca (LSE: AZN), RELX (LSE: REL) and Rolls-Royce Holdings (LSE: RR.), each backed by institutional conviction and operating in marke...
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and YMCA of the USA (Y-USA) announced today at the Aspen Ideas: Health conference, a five-year partnership focused on strengthening cancer education in t...
AIM Advances Phase 2 DURIPANC Study In Pancreatic Cancer; Expects Topline Data In Q1,2027
(RTTNews) - AIM ImmunoTech Inc. (AIM), an immuno-pharma company, announced that the final subject have received their first dose in the Phase 2 DURIPANC clinical trial evaluating its lead investigatio...
The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs
The investigation comes after Berlin said it would require drugmakers to offer bigger discounts on medicines.
U.S. opens tariff probe targeting Germany's drug pricing policies
The U.S. said the probe will examine whether "persistent underpayment" for medicines by Germany is discriminatory. "President Trump has made clear that American patients should not be shouldering a di...
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Ozempic Linked To Lower Risk Of Violence In New Study
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J...
The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics
Applied Materials, GE Aerospace and AstraZeneca headline Zacks research picks, backed by strong industry outperformance and key growth drivers.
Top Stock Reports for Applied Materials, GE & AstraZeneca
Today's Research Daily features new research reports on 16 major stocks, including Applied Materials, Inc. (AMAT), GE Aerospace (GE) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Team, I...
AstraZeneca (AZN) Faces Changes in Medicare Drug Price Negotiation Framework
AstraZeneca (AZN) Faces Changes in Medicare Drug Price Negotiation Framework
AstraZeneca (AZN) Receives Priority Review for Ultomiris Treatment Application
AstraZeneca (AZN) Receives Priority Review for Ultomiris Treatment Application